Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The company has market cap of $731.81 million. The Firm develops and commercializes supportive care products. It has a 99.28 P/E ratio. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
The stock of BRF SA (ADR) (NYSE:BRFS) gapped down by $0.06 today and has $11.15 target or 7.00% below today’s $11.99 share price. The 8 months technical chart setup indicates high risk for the $9.81 billion company. The gap down was reported on Apr, 6 by Barchart.com. If the $11.15 price target is reached, the company will be worth $686.70M less. About 826,029 shares traded. BRF SA (ADR) (NYSE:BRFS) has declined 25.97% since August 30, 2016 and is downtrending. It has underperformed by 34.10% the S&P500.
BRF S.A. is a multinational Brazilian firm that owns a diverse portfolio of products and is a producer of foods. The company has market cap of $9.81 billion. The Company’s divisions include Brazil, Latin America , Europe, Middle East and North of Africa (MENA), Asia, Africa and Other Segments. It currently has negative earnings. These divisions include sales of all distribution channels and activities subdivided in to poultry, pork and other, processed, and other sales.
Analysts await BRF SA (ADR) (NYSE:BRFS) to report earnings on April, 27. They expect $-0.07 EPS, down 800.00% or $0.08 from last year’s $0.01 per share. After $-0.17 actual EPS reported by BRF SA (ADR) for the previous quarter, Wall Street now forecasts -58.82% EPS growth.
Among 5 analysts covering BRF S.A. (NYSE:BRFS), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. BRF S.A. had 8 analyst reports since September 16, 2015 according to SRatingsIntel. On Monday, October 5 the stock rating was downgraded by Goldman Sachs to “Sell”. The firm earned “Neutral” rating on Wednesday, September 16 by JP Morgan. The rating was downgraded by Bank of America on Friday, October 30 to “Neutral”. The firm has “Buy” rating by Citigroup given on Thursday, October 8. JP Morgan downgraded the shares of BRFS in report on Monday, January 9 to “Neutral” rating. The rating was upgraded by JP Morgan on Tuesday, May 31 to “Overweight”. The stock of BRF SA (ADR) (NYSE:BRFS) has “Buy” rating given on Friday, January 29 by Deutsche Bank.
Orbimed Advisors Llc holds 0.71% of its portfolio in Insys Therapeutics Inc for 6.07 million shares. Regal Investment Advisors Llc owns 228,873 shares or 0.58% of their US portfolio. Moreover, Globeflex Capital L P has 0.19% invested in the company for 82,422 shares. The New York-based Jw Asset Management Llc has invested 0.18% in the stock. Ascend Capital Llc, a California-based fund reported 225,000 shares.
Since January 1, 0001, it had 1 buying transaction, and 0 insider sales for $107,489 activity.
